These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3678471)

  • 1. Potential value of vintristine-adriamycin-dexamethasone combination chemotherapy (VAD) in refractory and rapidly progressive myeloma.
    Collin R; Greaves M; Preston FE
    Eur J Haematol; 1987 Sep; 39(3):203-8. PubMed ID: 3678471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
    Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
    Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VAD chemotherapy for refractory multiple myeloma.
    Lokhorst HM; Meuwissen OJ; Bast EJ; Dekker AW
    Br J Haematol; 1989 Jan; 71(1):25-30. PubMed ID: 2644970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and toxicity of VAD in the treatment of myeloma and related disorders.
    Sheehan T; Judge M; Parker AC
    Scand J Haematol; 1986 Nov; 37(5):425-8. PubMed ID: 3810040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VAD protocol for treatment of advanced refractory multiple myeloma.
    Scheithauer W; Cortelezzi A; Kutzmits R; Baldini L; Ludwig H
    Blut; 1987 Sep; 55(3):145-52. PubMed ID: 3620710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VAD-based regimens as primary treatment for multiple myeloma.
    Alexanian R; Barlogie B; Tucker S
    Am J Hematol; 1990 Feb; 33(2):86-9. PubMed ID: 2301376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma.
    Young RI; Ranson M; Chang J; Lord B; Testa N; Scarffe JH
    Eur J Cancer; 1997 Feb; 33(2):307-11. PubMed ID: 9135507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen.
    Stenzinger W; Blömker A; Hiddemann W; van de Loo J
    Blut; 1990; 61(2-3):55-9. PubMed ID: 2207342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
    Ross DM; To LB; Horvath N
    Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.
    Gertz MA; Kalish LA; Kyle RA; Hahn RG; Tormey DC; Oken MM
    Am J Clin Oncol; 1995 Dec; 18(6):475-80. PubMed ID: 8526187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].
    Adam Z; Elbl L; Vorlícek J; Hájek R; Tomíska M; Hejlová N; Králová E; Novotná H
    Vnitr Lek; 1994 Aug; 40(8):506-12. PubMed ID: 7941437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
    van der Spek E; Bloem AC; Sinnige HA; Lokhorst HM
    Haematologica; 2007 Dec; 92(12):e130-1. PubMed ID: 18055977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
    Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ambulatory therapy of multiple myeloma with vincristine, adriamycin and dexamethasone].
    Egerer G; Hegenbart U; Salwender H; Hahn U; Haas R; Goldschmidt H; Hunstein W
    Dtsch Med Wochenschr; 1997 Apr; 122(17):531-5. PubMed ID: 9190299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.